COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA

被引：0
|
作者：
Xu, J. [1 ]
Lan, K. [2 ]
Wang, J. [3 ]
机构：
[1] Zhejiang Univ, Hangzhou, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[3] Wuhan Univ, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB19
引用
收藏
页码：S111 / S111
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Liu, C.
    Tao, L. B.
    Wang, F.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [2] Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China
    James L. Palmer
    Amélie Beaudet
    Jeremy White
    Juliette Plun-Favreau
    Jayne Smith-Palmer
    [J]. Advances in Therapy, 2010, 27 : 814 - 827
  • [3] Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China
    Palmer, James L.
    Beaudet, Amelie
    White, Jeremy
    Plun-Favreau, Juliette
    Smith-Palmer, Jayne
    [J]. ADVANCES IN THERAPY, 2010, 27 (11) : 814 - 827
  • [4] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
    Saiyarsarai, P.
    Khosroshahi, Ghazizadeh A.
    Khedmati, J.
    Ghaffari, S.
    Soleymani, F.
    Seyyedifar, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S576 - S576
  • [5] COST-EFFECTIVENESS ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS INSULIN GLARGINE IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
    Xu, Z.
    Han, P.
    Wei, Y.
    Zhang, Y.
    Wu, J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A247 - A247
  • [6] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [7] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes
    Cheng, Huafeng
    Wan, Xu
    Ma, Jing
    Wu, Bin
    [J]. CLINICAL THERAPEUTICS, 2019, 41 (03) : 445 - 455
  • [8] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Zhou, L.
    Zhou, N.
    Hu, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
  • [9] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Kondo, Yuichiro
    Katamine, Aki
    Shimizu, Mika
    Kubota, Ryo
    Suda, Rika
    Babazono, Tetsuya
    [J]. DIABETOLOGY INTERNATIONAL, 2024, 15 (02) : 237 - 243
  • [10] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Junko Oya
    Tomoko Nakagami
    Yukiko Hasegawa
    Yuichiro Kondo
    Aki Katamine
    Mika Shimizu
    Ryo Kubota
    Rika Suda
    Tetsuya Babazono
    [J]. Diabetology International, 2024, 15 : 237 - 243
12345